Author:
Friedrich C.,Ring A.,Brand T.,Sennewald R.,Graefe-Mody E. U.,Woerle H.-J.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference32 articles.
1. Aspen Europe GmbH (2010) Lanoxin 125 Tablets, Summary of Product Characteristics (last updated 8 March 2010). http://www.medicines.org.uk/EMC/medicine/2174/SPC/Lanoxin+125+Tablets/ . Accessed 17 Nov 2010
2. Balimane PV, Chong S (2005) A combined cell based approach to identify P-glycoprotein substrates and inhibitors in a single assay. Int J Pharmacol 301:80–88
3. Barnett AH, Harper R, Toorawa R, Patel S, Woerle H-J (2010) Linagliptin monotherapy improves glycaemic control in type 2 diabetes patients for whom metformin therapy is inappropriate. Diabetologia 53(Suppl 1):S327 (Poster 823, presented at the European Association for the Study of Diabetes 46th Annual Meeting, Stockholm, Sweden. 20–24 September 2010)
4. Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, Withopf B, Wagner K (2010) The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos 38:667–678
5. Deacon CF, Holst JJ (2010) Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs 19:133–140
Cited by
39 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献